Tag: CLEAR

CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)

Coronary/Structural Heart by 0 comments

– Positive CLEAR Outcomes data to be presented as a Late-Breaking Clinical Trial (LBCT) at ACC.23/WCC on March 4, 2023 – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events […]

Continue Reading →

Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative risk reduction in major adverse CV events

Coronary/Structural Heart by 0 comments

Successful topline results from the CLEAR Outcomes Trial demonstrate that bempedoic acid, marketed as NILEMDO®▼ in Europe, reduces the risk of serious cardiovascular (CV) events in patients with, or who are at, high risk for atherosclerotic cardiovascular disease (ASCVD) with […]

Continue Reading →